Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIC trial of IMU-838 plus oseltamivir for hospitalized COVID-19
ISRCTN53038326Phase 2Completed
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
- Start
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of vidofludimus calcium and oseltamivir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Primary endpoint: Time to clinical improvement. Started Jun 2020; status: completed.
02
Drugs
vidofludimus calciumoseltamivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN53038326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53038326.